Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2, Observer-Blind, Controlled, Randomized, Multi-Center Extension Study to Evaluate Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY in Adolescents Who Previously Received the Same Study Vaccines

NCT01367158 is registered in ClinicalTrials.gov with Novartis Vaccines as lead sponsor.

NCT NCT01367158
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01367158 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2, Observer-Blind, Controlled, Randomized, Multi-Center Extension Study to Evaluate Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY in Adolescents Who Previously Received the Same Study Vaccines
Lead sponsor
Novartis Vaccines
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2011
Completion date
July 31, 2012
Enrollment
440 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

meningococcal disease, meningococcal meningitis